Psychedelic Medicine
Association
Psychedelic Medicine
Association
President, Psychedelic Medicine Association
Senior Counsel, Husch Blackwell; Co-Founder & Co-Lead, Psychedelic and Emerging Therapies Practice Group
Kimberly is the co-founder and co-lead of Husch Blackwell’s Psychedelic and Emerging Therapies practice group. Kimberly’s background in biotech startups as a research scientist gives her a unique perspective in emerging areas of law such as psychedelic therapeutics. She is a problem solver and regulatory compliance advisor for innovators and clinicians engaged in the research and commercialization of novel therapies. Kim is inspired and motivated by the potential use of psychedelic therapeutics to treat debilitating mental health conditions such as PTSD. Stakeholders look to her expert guidance through the web of legal complexities at the state and federal levels as these novel therapies proceed through the clinical trial process.
Senior Counsel, Husch Blackwell; Co-Founder & Co-Lead, Psychedelic and Emerging Therapies Practice Group
A co-founder and co-leader of the firm’s Psychedelics and Emerging Therapies Practice Group, Natasha advises clients on the regulatory matters inherent in new drug development. She also advises behavioral health clients on compliance matters. With great personal passion for the promise of psychedelics and other new drugs, Natasha is well-versed in historical and current psychedelic research, including FDA-approved studies on MDMA and psilocybin use for mental health and end-of-life issues, the legalization and decriminalization of psylocibin in numerous cities and states, and biotech and pharmaceutical research. She’s enthusiastic about the potential of these drugs to treat and potentially cure a variety of mental health needs, and she’s fascinated by the drug development process. Natasha is motivated to help clients help the world, and she’s equally dedicated to ensuring that underrepresented communities have access to new treatments.
Partner, Husch Blackwell; Co-Founder & Co-Lead, Psychedelic and Emerging Therapies Practice Group
Karen is the co-founder and co-lead of the firm’s Psychedelic and Emerging Therapies practice group. This groundbreaking group guides researchers, manufacturers, investors, clinicians and other participants around and through the myriad obstacles that result from the patchwork of state and federal laws regulating Schedule I controlled substances. She is well versed in complex litigation involving toxic products, materials and chemicals. Karen regularly represents clients in state and federal court in matters of product liability, premises liability, personal injury and other complex allegations. She is known for her ability to defend client reputation along with the legal claims at hand.
Chief Medical Officer at Novamind/Co-founder at Cedar Psychiatry
Dr. Reid Robison is a board-certified psychiatrist and Chief Medical Officer at Novamind. Reid is co-founder at Cedar Psychiatry and serves as Medical Director of Center for Change, a top Eating Disorder program. He is currently the coordinating investigator for the MAPS MDMA-assisted Psychotherapy study of Eating Disorders. Reid is adjunct faculty at the University of Utah, founder of the Polizzi Free Clinic, and provides medical support and psychedelic therapy at plant medicine retreats abroad.
The availability of psychedelic medicine varies widely depending on what country, state, and city a patient lives in—and so as practitioners, it can be difficult to know what’s legally available when evaluating which therapeutics may benefit your patients.
What makes things even more confusing is that for the widely available legal psychedelics, namely ketamine, there are no currently established standards for whether ketamine treatments should include a therapeutic component, and, if so, what certification that therapist should have.
So you may have questions, like, “How can I legally discuss potentially illegal substances with my patients?” and “How can I refer to a ketamine clinic or a clinical trial and protect both my patient and myself?”
This month we are truly fortunate to have three attorneys who are well-versed in these areas to help answer some of your pressing legal questions, including:
…and much more!
As always, there will be ample time for audience Q&A, so you’ll get to interact with the panelists directly!
So please join us for this live panel discussion on Thursday, October 24th at 5 pm Pacific, 8 pm Eastern. This is exclusively for members of the Psychedelic Medicine Association, so if you have not yet registered, please do so here. A link to the recording will be available afterward if you cannot make it to the live event.
You can find the Psychedelic Medicine Association on Twitter, LinkedIn, and on Facebook.